STM3006 is a highly potent, selective and orally active METTL3 inhibitor (IC50: 5 nM). STM3006 can be used for the research of acute myeloid leukaemia (AML).
References:
[1]. Andrew A Guirguis, et al. Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.Cancer Discov. 2023 Oct 5;13(10):2228-2247.
















